Volanesorsen for treating familial chylomicronaemia syndrome

that this was not in line with the patient testimonies, which indicated that FCS substantially affects every aspect of their lives. One patient expert explained that the EQ-5D does not measure the aspects of quality of life that FCS affects, for example, strict adherence to a low-fat diet and the effect of that on their family and social lives. The committee noted that the EQ-5D does not contain questions about difficulties posed by the restricted diet, but does measure usual activities, pain and anxiety. Another patient expert noted that people with FCS may have adapted because living with the condition is their normal (for example, the fear of having AP, restrictions to usual activities related to dietary restrictions), so no difference from baseline would be detected. The committee recognised that the intermittent symptoms of FCS might explain why a one-off questionnaire might not fully capture its effect on quality of life. But it did not think that the clinical trial results showed that volanesorsen had no effect on quality of life. Adverse events 4.16 The committee discussed the adverse events reported in the 2 main clinical trials. Common events (occurring in between 1 in 100 or more and fewer than
